ArticleThe Journal of pathology2014
Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
Article in The Journal of pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015Guideline
- The uterine secretome initiates growth of gynecologic tissues in ectopic locations: re-evaluating the evidence.Pathology oncology research : POR · 2026Review
- Early Genetic Divergence of High-Grade Carcinomas Originating from Low-Grade Serous Ovarian Neoplasms.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025Article
- Targeting BRAF pathway in low-grade serous ovarian cancer.Journal of gynecologic oncology · 2024Review
- KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.Virchows Archiv : an international journal of pathology · 2023Article
- Do Exophytic and Endophytic Patterns in Borderline Ovarian Tumors Have Different Prognostic Implications? A Large Multicentric Experience.Journal of clinical medicine · 2023Article
- Oncogenic BRAF and KRAS mutations in endosalpingiosis.The Journal of pathology · 2020Article
- The Diagnosis, Treatment, Prognosis and Molecular Pathology of Borderline Ovarian Tumors: Current Status and Perspectives.Cancer management and research · 2020Review
- High Frequency ofDiagnostics (Basel, Switzerland) · 2019Article
- Article
- Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.The American journal of surgical pathology · 2019Article
- [Pitfalls and common problems in the differential diagnosis of epithelial ovarian tumors].Der Pathologe · 2019Review
- Identification of TRA-1-60-positive cells as a potent refractory population in follicular lymphomas.Cancer science · 2019Article
- BRAFHistopathology · 2018Article
- A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract.Seminars in diagnostic pathology · 2018Review
- KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.Medicines (Basel, Switzerland) · 2018Review
- Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes.Advances in cancer research · 2018Review
- Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.Human pathology · 2017Article
- Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
Abstract
There is debate as to whether peritoneal implants associated with serous borderline tumours/atypical proliferative serous tumours (SBT/APSTs) of the ovary are derived from the primary ovarian tumour or arise independently in the peritoneum. We analysed 57 SBT/APSTs from 45 patients with advanced-stage disease identified from a nation-wide tumour registry in Denmark. Mutational analysis for hotspots in KRAS and BRAF was successful in 55 APSTs and demonstrated KRAS mutations in 34 (61.8%) and BRAF mutations in eight (14.5%). Mutational analysis was successful in 56 peritoneal implants and revealed KRAS mutations in 34 (60.7%) and BRAF mutations in seven (12.5%). Mutational analysis could not be performed in two primary tumours and in nine implants, either because DNA amplification failed or because there was insufficient tissue for mutational analysis. For these specimens we performed VE1 immunohistochemistry, which was shown to be a specific and sensitive surrogate marker for a V600E BRAF mutation. VE1 staining was positive in one of two APSTs and seven of nine implants. Thus, among 63 implants for which mutation status was known (either by direct mutational analysis or by VE1 immunohistochemistry), 34 (53.9%) had KRAS mutations and 14 (22%) had BRAF mutations, of which identical KRAS mutations were found in 34 (91%) of 37 SBT/APST-implant pairs and identical BRAF mutations in 14 (100%) of 14 SBT/APST-implant pairs. Wild-type KRAS and BRAF (at the loci investigated) were found in 11 (100%) of 11 SBT/APST-implant pairs. Overall concordance of KRAS and BRAF mutations was 95% in 59 of 62 SBT/APST-implant (non-invasive and invasive) pairs (p < 0.00001). This study provides cogent evidence that the vast majority of peritoneal implants, non-invasive and invasive, harbour the identical KRAS or BRAF mutations that are present in the associated SBT/APST, supporting the view that peritoneal implants are derived from the primary ovarian tumour.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.